ExodusPoint Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

ExodusPoint Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$149K	Buy	+25,685	New	+$170K	﹤0.01%	1410
2025 Q4	–	Sell	-86,920	Closed	-$708K	–	2137
2025 Q3	$708K	Buy	+86,920	New	+$577K	0.01%	1077
2024 Q4	–	Sell	-84,740	Closed	-$242K	–	2128
2024 Q3	$242K	Buy	+84,740	New	+$218K	﹤0.01%	1419
2023 Q4	–	Sell	-185,221	Closed	-$345K	–	2119
2023 Q3	$345K	Buy	+185,221	New	+$424K	﹤0.01%	1378
2022 Q4	–	Sell	-20,528	Closed	-$32K	–	2203
2022 Q3	$32K	Sell	20,528 -36,266	-64%	-$60K	﹤0.01%	1803
2022 Q2	$87K	Sell	56,794 -453,164	-89%	-$956K	﹤0.01%	1756
2022 Q1	$1.3M	Buy	509,958 +469,564	+1,162%	+$1.15M	0.02%	990
2021 Q4	$118K	Buy	+40,394	New	+$87.3K	﹤0.01%	1929
2020 Q4	–	Sell	-16,867	Closed	-$100K	–	2434
2020 Q3	$100K	Sell	16,867 -15,715	-48%	-$62.8K	﹤0.01%	1589
2020 Q2	$87K	Buy	+32,582	New	+$113K	﹤0.01%	1647
2020 Q1	–	Sell	-47,000	Closed	-$331K	–	1700
2019 Q4	$331K	Buy	+47,000	New	+$388K	0.01%	1101

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ExodusPoint Capital Management's XERS Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 25,685 shares worth $149K. The stake represents ﹤0.01% of the portfolio and ranks #1410 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in XERS as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in XERS in Q4 2019 and has held it in 11 quarters since. The position peaked at $1.3M in Q1 2022. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

ExodusPoint Capital Management held 25,685 shares of Xeris Biopharma Holdings worth $149K as of Q1 2026.
Xeris Biopharma Holdings was a new ExodusPoint Capital Management position in Q1 2026.
Xeris Biopharma Holdings made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1410 holding.
ExodusPoint Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2019 and has held it in 11 quarters since.
ExodusPoint Capital Management's Xeris Biopharma Holdings position peaked at $1.3M in Q1 2022.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.